Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grapiprant + Pembrolizumab in NSCLC
NCT03696212Phase 2Terminated
- Sponsor
- Arrys Therapeutics, Inc.
- Start
- Jan 2019
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of grapiprant in lung adenocarcinoma (LUAD), sponsored by Arrys Therapeutics, Inc. Primary endpoints: Safety and tolerability of grapiprant in combination with pembrolizumab, Recommended Phase 2 Dose and 1 more. Started Jan 2019; status: terminated.
02
Drugs
grapiprant
03
Conditions
lung adenocarcinoma (LUAD)
Beyond the preview
Go deeper on NCT03696212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696212.